Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

[1] Natoli JL(2010)Global prevalence of chronic migraine: a systematic review Cephalalgia 30 599-609

[2] Manack A(2018)The international classification of headache disorders, 3rd edition Cephalalgia 38 1-211

[3] Dean B(2017)Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease Arq Neuropsiquiatr 75 153-159

[4] Butler Q(2015)Functional alterations of pain processing pathway in migraine patients with cutaneous allodynia Pain Med 16 1211-1220

[5] Turkel CC(2017)Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study Headache 57 1026-1040

[6] Stovner L(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial Cephalalgia 30 793-803

[7] Lipton RB(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalalgia 30 804-814

[8] Benatto MT(2010)OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program Headache 50 921-936

[9] Florencio LL(2011)OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program Headache 51 1358-1373

[10] Carvalho GF(2015)Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine BMC Neurol 15 S20-S28

[1] Natoli JL(2010)Global prevalence of chronic migraine: a systematic review Cephalalgia 30 599-609

[2] Manack A(2018)The international classification of headache disorders, 3rd edition Cephalalgia 38 1-211

[3] Dean B(2017)Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease Arq Neuropsiquiatr 75 153-159

[4] Butler Q(2015)Functional alterations of pain processing pathway in migraine patients with cutaneous allodynia Pain Med 16 1211-1220

[5] Turkel CC(2017)Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study Headache 57 1026-1040

[6] Stovner L(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial Cephalalgia 30 793-803

[7] Lipton RB(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalalgia 30 804-814

[8] Benatto MT(2010)OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program Headache 50 921-936

[9] Florencio LL(2011)OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program Headache 51 1358-1373

[10] Carvalho GF(2015)Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine BMC Neurol 15 S20-S28